Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health, Inc. is asking stockholders to approve, pursuant to Nasdaq Listing Rule 5635(d), the potential issuance of Common Stock to C/M Capital Master Fund, LP that could exceed 19.99% of shares outstanding. The proxy seeks approval for two financings: an equity line of credit to sell up to $40,000,000 of Common Stock and a private preferred-stock purchase (Series P) tied to up to $2,400,000 stated value, plus $72,000 in Commencement Shares. Shares outstanding were 14,044,277 as of April 15, 2026. The filings describe mechanics, limits (a 4.99% beneficial ownership cap, increaseable to 9.99% by notice), registration rights, dilution examples at various prices, and a board-backed proposal to allow adjournment to solicit additional proxies for these approvals.
Jaguar Health, Inc. increased its authorized share capacity following approval at a Special Meeting of stockholders held on April 20, 2026. Stockholders approved a Tenth Amendment to the company’s Third Amended and Restated Certificate of Incorporation to raise authorized voting common stock from 298,000,000 shares to 500,000,000 shares. The total number of shares the company is authorized to issue rose from 352,475,074 shares to 554,475,074 shares. The board approved this Authorized Share Increase and filed the Tenth Amendment with the Delaware Secretary of State, where it became effective immediately upon filing. All five proposals presented at the Special Meeting were approved, with 7,181,767 shares represented out of 12,419,277 shares entitled to vote as of the March 2, 2026 record date.
Jaguar Health, Inc. reports that it previously had a stockholders’ deficit of approximately $18.7 million as of December 31, 2025, which did not satisfy Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5 million in stockholders’ equity.
The company now believes its stockholders’ equity as of April 7, 2026 exceeded $2.5 million, after a series of transactions. These include $16.0 million of non-dilutive capital under a License Agreement with Napo Pharmaceuticals, Woodward Specialty and Future Pak, $3.0 million received after termination of a buy-back provision, and approximately $1.0 million from Woodward’s purchase of existing product inventory under a Supply Agreement.
Additional items are $2.0 million to be received upon satisfaction of Third Party Replacement MSA Conditions, approximately $1.2 million to be received from Mytesi product sales under a Firm Order, about $0.2 million from earlier Mytesi net sales, roughly $0.2 million of grant revenue, and an approximate $3.4 million gain on partial extinguishment of debt owed to affiliates of Chicago Venture Partners, L.P. The company cautions that these are forward-looking statements subject to risks discussed in its 2025 Form 10-K.
Jaguar Health reported 2025 results showing slightly lower sales but much higher losses, while also securing new licensing cash. Net product revenue for the year was $11.5 million, down about 1.5% from 2024. Loss from operations widened to $45.9 million from $30.8 million, and net loss attributable to common stockholders grew to $53.6 million from $38.5 million. Non-GAAP EBITDA was a loss of $48.2 million, larger than the $36.0 million non-GAAP EBITDA loss in 2024. The company noted net revenue rose 5% in the fourth quarter versus the third quarter of 2025.
In January 2026, Jaguar received an upfront payment of $16 million in non-dilutive capital under a U.S. license agreement with Future Pak for its crofelemer drugs Mytesi and Canalevia-CA1, with an additional $2 million payable upon post-closing conditions and $3.0 million already received of up to $20 million in potential milestone and other future payments. The company plans to appeal Nasdaq’s March 5, 2026 noncompliance determination related to Nasdaq Listing Rule 5550(a)(2) at a hearing on April 7, 2026, and delisting is stayed pending the panel’s final decision.
Jaguar Health, Inc. details a diversified gastrointestinal drug business built around crofelemer and related plant-derived therapies. The company licensed U.S. rights to Mytesi and Canalevia-CA1 to Future Pak in January 2026, receiving $16 million in non‑dilutive capital plus a further $2 million tied to post‑closing conditions and eligibility for up to $20 million in milestones. An additional $3.0 million payment followed termination of a buy‑back provision, while Jaguar retains manufacturing responsibilities.
The filing highlights advanced development of a highly concentrated crofelemer powder for oral solution targeting ultra‑rare intestinal failure indications, including microvillus inclusion disease and short bowel syndrome with intestinal failure, supported by multiple orphan drug designations in the U.S. and EU and early proof‑of‑concept data showing parenteral support reductions of up to 37%. Jaguar also pursues NP‑300 for infectious diarrhea with potential access to a tropical disease priority review voucher, markets Gelclair for oral mucositis under a U.S. in‑license, and develops plant‑based mental health drugs through the Magdalena joint venture.
Jaguar Health, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 due to delays compiling material subsequent-event information. The company states it will file the Form 10-K no later than the fifteenth calendar day following the prescribed due date.
Jaguar Health has called a special stockholder meeting to reshape its capital structure. Stockholders will vote on raising authorized voting common shares from 298,000,000 to 500,000,000, increasing total authorized shares to 554,475,074. As of March 2, 2026, 12,419,277 common shares were outstanding.
The board is also seeking authority for two separate reverse stock splits, each at a ratio between 1‑for‑15 and 1‑for‑150, which together could reach an aggregate ratio of up to 1‑for‑22,500 if both are implemented. The board would choose exact ratios and timing within one year of approval for each split.
Another key proposal asks approval, under Nasdaq Listing Rule 5635(d), for issuing common shares upon exchange of a secured promissory note originally totaling $10,810,000 held by Streeterville Capital, LLC. Full exchange of the outstanding balance as of March 12, 2026 could exceed the current share count, meaning substantial potential dilution for existing holders. The board also seeks authority to adjourn the meeting if more time is needed to secure votes.
Jaguar Health, Inc. is asking shareholders to approve multiple capital-structure actions at a Special Meeting on April 20, 2026
The proposals seek (i) to increase authorized voting Common Stock from 298,000,000 to 500,000,000 (total authorized shares from 352,475,074 to 554,475,074); (ii) and (iii) to authorize two discretionary reverse stock splits, each at a ratio between 1-for-15 and 1-for-150; and (iv) to approve, for Nasdaq Rule 5635(d) purposes, the issuance of shares on exchange of a secured promissory note issued to Streeterville Capital with original principal $10,810,000 (outstanding approximately $7,057,500 as of March 12, 2026), which could result in issuance of ~13,232,241 Exchange Shares (about 106.55% of the 12,419,277 shares outstanding as of the Record Date).
The company disclosed Nasdaq non-compliance for a sub-$1 bid price and has appealed; approvals are requested under both the Votes Cast Standard and the Majority of Outstanding Standard to preserve board flexibility. Shareholder votes will also permit adjournments to solicit additional proxies.
Jaguar Health director John Micek received equity awards as board compensation. On December 11, 2025 he was granted stock options for 7,377 shares of common stock at an exercise price of $1.44 per share, expiring on December 11, 2035, under the 2014 Stock Incentive Plan. The options vest monthly over 12 months while he continues serving on the boards of Jaguar Health and its subsidiary Napo Therapeutics.
On the same date he also received 7,377 restricted stock units, each representing one share of common stock, which vest on December 11, 2026. After the grant he directly holds 7,430 common shares, and the vested RSU shares will be delivered on the vesting date specified in the grant notice.
Jaguar Health, Inc. reworked several financing arrangements with Uptown Capital and Streeterville Capital. The company postponed monthly royalty payments under two $12 million royalty interests from April 1, 2026 to July 1, 2026 and reduced each related Royalty Repayment Amount by ten percent, to $11,125,282.54 and $12,428,782.20. Jaguar and subsidiary Napo Pharmaceuticals also amended secured notes with Streeterville: the 2021 Note’s maturity was extended to July 1, 2026 and its Outstanding Balance cut ten percent to $6,596,304.11, while the 2025 Note’s maturity was extended to March 12, 2029 with an Outstanding Balance of $7,048,021.86. Napo granted Streeterville a security interest in specified Lechlemer and TDPRV collateral to secure the 2025 Note. In a separate warrant termination agreement, investors agreed to terminate warrants exercisable for 48,211 shares of Jaguar’s common stock.